Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 404-986-7 | CAS number: 74227-35-3 BDS-HEXAFLUOROPHOSPHATE; BDS-HEXAFLUORPHOSPHAT; ESACURE 1004
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- This study was included in the Notification dossier of the first Notifier (1989); since under Directive 67/548/EEC the studies of the first notifier were not included in the dossier, Lamberti has the letter of Access, but not the complete study report. The study can be considered reliable since already evaluated by the Authority.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 409 (Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents)
- GLP compliance:
- not specified
Test material
- Reference substance name:
- A mixture of: thiobis(4,1-phenylene)-S,S,S',S'-tetraphenyldisulfonium bishexafluorophosphate; diphenyl(4-phenylthiophenyl)sulfonium hexafluorophosphate
- EC Number:
- 404-986-7
- EC Name:
- A mixture of: thiobis(4,1-phenylene)-S,S,S',S'-tetraphenyldisulfonium bishexafluorophosphate; diphenyl(4-phenylthiophenyl)sulfonium hexafluorophosphate
- Cas Number:
- 74227-35-3
- Molecular formula:
- C36H28F12P2S3 (80%); C24H19F6PS2 (13%)
- IUPAC Name:
- A mixture of: thiobis(4,1-phenylene)-S,S,S',S'-tetraphenyldisulfonium bishexafluorophosphate; diphenyl(4-phenylthiophenyl)sulfonium hexafluorophosphate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Not available
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
6.81 mg/kg/day
Basis:
no data
- Remarks:
- Doses / Concentrations:
21.5 mg/kg/day
Basis:
no data
- Remarks:
- Doses / Concentrations:
68.1 mg/kg/day
Basis:
- Remarks:
- Doses / Concentrations:
215 or 464 mg/kg/day
Basis:
- No. of animals per sex per dose:
- Not available
- Control animals:
- not specified
- Details on study design:
- In order to be certain about reaching the toxic range, the high dosage was increased on the 38th treatment day from 215 to 464 mg/kg/day.
Results and discussion
Results of examinations
- Details on results:
- No toxic effects were observed at doses of 21,5-68,1 mg/kg/day
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 6.81 mg/kg bw/day (nominal)
- Based on:
- not specified
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
After the dosage increase, 6 males died between the 7th and 13th weeks as did one female in the 9th week. A female from a medium dose group died as a result of incorrect application.
A clear impairment of the feed intake, clear weight-loss and impairment of the general state of health were observable in the high dosage group up to three weeks after the dosage increase. After this period the state of health of the surviving animals stabilised once more and the difference in the absolute body weights at the end of the test amounted to less than 10% when compared with the controls.
A slight decrease in the number of thrombocytes was established for both sexes in the high-dose group. Only the females in this dose group showed changes in the differential blood picture. The parameters measured in the 7th and 14th weeks revealed a slight increase in the activity of the transaminase as well as an inhibition of the cholinesterase. There were increased values for the total N as well as decreased values for bilirubin and triglyceride.
There were increases in the absolute and relative organ masses for the thyroid and adrenal glands as well as for the liver and kidney in the animals from the high-dose group. There were also increases in thyroid gland masses among animals from the 68.1 mg/kg group. There were some increases in liver masses among the females from this group. Enlarged thyroids were revealed macroscopically in the animals from the high-dose group.
The main finding of the histological investigation was likewise a marked hyperplasia of the thyroid follicular epithelia with a reduction in the area covered by colloidal follicles (Struma parenchymatosa diffusa) in the animals from the high-dose group and to a lesser extent also in some animals from the two medium-dose groups. An increased number of basophilic cells as well as vacuolar and enlarged basophilic cells were found in the pituitaries of the male animals in the high-dose group. Dose-related hypertrophies of the cells in the Zona granulosa and fasciculata were found in the adrenal glands of the animals from the high and up-per-middle dose group. These changes also occurred in low dosage groups and even in some control animals at a low level of markedness and at a low frequency.
Proliferating breast tissue and congested secretion parts in the proliferating glands could be found in all male animals. This finding was most frequent and most pronounced in terms of its degree of seriousness in the males from the high-dose group.
In addition, findings relating to the liver and kidneys (centrolobular hepatocellular vacuolization and hypertrophy or oil-red positive inclusions in proximal tubular epithelia of the kidney) were diagnosed in the animals from the high dose group. All of the other findings corresponded to the spontaneous pathological spectrum of the age group of the species.
Applicant's summary and conclusion
- Conclusions:
- According to the study results the NOEL for oral application to rats over 90 days amounts to 6.81 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.